Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: The INSTIGATE Study;Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE

Endocrinologia y Nutricion

Volumn 58, Issue 6, 2011, Pages 274-282

  Costi, María ^a   Smith, Helen ^b   Reviriego, Jesús ^a   Castell, Conxa ^c   Goday, Alberto ^d   Dilla, Tatiana ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b European Outcomes Research   (United Kingdom)

^c GENERALITAT DE CATALUNYA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Diabetes mellitus; Health care costs; Insulin therapy; Prospective studies; Spain; Type 2

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION COST; HUMAN; INSULIN TREATMENT; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEALTH EXPENDITURES; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OFFICE VISITS; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 79960414735     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.03.004     Document Type: Article

References (29)

1. World Health Organization [portal en internet] Prevalence of diabetes worldwide; © WHO 2011 [citado 28/9/2009]. Disponible en: http://www.who.int/diabetes/facts/world_figures/en/index.html.
2. Ministerio de Sanidad: Estrategia en Diabetes del SNS [citado 15/7/2010]. Disponible en: http://www.sediabetes.org/gestor/upload/estrategia_diabetes_sistema_naci onal_salud.pdf.
3. Valdés S., Rojo-Martínez G., Soriguer F. Evolución de la prevalencia de la diabetes tipo 2 en población adulta española. Med Clin 2007, 129:352-355.
4. Fu A.Z., Qiu Y., Radican L., Wells B.J. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care 2009, 32:2187-2192.
5. Oliva J., Lobo F., Molina B., Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004, 27:2616-2621.
6. Hart W., Espinosa C., Rovira J. El coste de la diabetes mellitus conocida en España. Med Clin 1997, 109:289-293.
7. Ballesta M., Carral F., Olveira G., Girón J.A., Aguilar M. Economic cost associated with type II diabetes in Spanish patients. Eur J Health Econ 2006, 7:270-275.
8. González P., Faure E., Del Castillo A. Coste de la diabetes mellitus en España. Med Clin (Barc) 2006, 127:776-784.
9. Bottomley J.M., Raymond F.D. Pharmaco-economic issues for diabetes therapy. Best Pract Res Clin Endocrinol Metab 2007, 21:657-685.
10. Hoerger T.J. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes. Med Care 2009, 47(Suppl 1):S21-27.
11. Jendle J.H. Resource utilisation and costs for the treatment of diabetes in the developed world: an economical burden that needs to be solved. Int J Clin Pract 2009, 63:980-982.
12. Liebl A., Breitscheidel L., Nicolay C., Happich M. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008, 24:2349-2358.
13. Jones S., Benroubi M., Castell C., Goday A., Liebl A., Timlin L. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009, 25:691-700.
14. Costi M., Dilla T., Reviriego J., Castell C., Goday A. Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation. INSTIGATE observational study in Spain. Acta Diabetol 2010, 47(Suppl 1):S169-175.
15. Oblikue Consulting eSALUD - Información económica del sector sanitario [citado 15/7/2010]. Disponible en: http://www.oblikue.com/bddcostes.
16. Consejo General de Colegios oficiales de Farmacéuticos: BOT base de datos de precios de fármacos [citado en 2008]. Disponible en: http://www.botplusweb.portalfarma.com/.
17. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
18. Mata M., Antoñanzas F., Tafalla M., Sanz P. El coste de la diabetes tipo 2 en Espana. El estudio CODE-2. Gac Sanit 2002, 16:511-520.
19. The International Diabetes Federation [portal en internet]. Global Guidelines for type 2 diabetes, chapter 6: Glucose control levels; © 2005 [citado 15/7/2010]. Disponible en: http://www.idf.org/node/1285?node=1457.
20. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
21. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
22. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
23. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
24. Rosenblum M.S., Kane M.P. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003, 9:309-316.
25. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States. Diabetes Care 2007, 30:1281-1282.
26. Fabunmi R., Nielsen L.L., Quimbo R., Schroeder B., Misurski D., Wintle M., et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009, 25:777-786.
27. Fuhr J.P., He H., Goldfarb N., Nash D.B. Use of chromium picolinate and biotin in the management of type 2 diabetes: an economic analysis. Dis Manag 2005, 8:265-275.
28. Athyros V.G., Hatzitolios A., Karagiannis A., Didangelos T.P., Iliadis F., Dolgyras S. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009, 25:1931-1940.
29. Minshall M.E., Roze S., Palmer A.J., Valentine W.J., Foos V., Ray J., et al. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clin Ther 2005, 27:940-950.